SCHEMBL3817784

SCHEMBL3817784

CCC(=C(c1ccc(OC)cc1)c1ccc(OC)cc1)c1ccc(OCCO)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 3/20 0.73
CYP19A1 P11511 10/20 0.70
ESR1 P03372 12/20 0.58
ESR2 Q92731 9/20 0.58
CYP3A4 P08684 4/20 0.58
CYP1A2 P05177 3/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2A6 P11509 2/20 0.58
CYP3A5 P20815 2/20 0.58
MAPT P10636 2/20 0.56
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
PRKD3 O94806 1/20 0.56
ABCB11 O95342 1/20 0.56
EGFR P00533 1/20 0.56
GBA1 P04062 1/20 0.56
NR3C1 P04150 1/20 0.56
ERBB2 P04626 1/20 0.56
TP53 P04637 1/20 0.56
PRKCG P05129 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3829896 0.88 NR1I2 (0.59) NR1I2CYP19A1ESR1ESR2CYP3A4
SCHEMBL4620166 0.88 CYP19A1 (0.89) NR1I2CYP19A1ESR1ESR2CYP3A4
SCHEMBL11370966 0.88 CYP19A1 (0.89) NR1I2CYP19A1ESR1ESR2CYP3A4
SCHEMBL3813077 0.88 CYP19A1 (0.89) NR1I2CYP19A1ESR1ESR2CYP3A4
SCHEMBL4620164 0.88 CYP19A1 (0.89) NR1I2CYP19A1ESR1ESR2CYP3A4
SCHEMBL31167386 0.82 CYP19A1 (1.00) CYP19A1ESR1ESR2CYP3A4CYP1A2
SCHEMBL14391816 0.81 CYP19A1 (0.67) NR1I2CYP19A1ESR1ESR2CYP3A4
SCHEMBL77535 0.81 ALDH1A1 (0.60) NR1I2ESR2CYP3A4MAPTDRD2
SCHEMBL10780099 0.80 PTGS2 (0.76) NR1I2CYP19A1ESR1ESR2CYP3A4
SCHEMBL10777096 0.80 ESR1 (0.75) NR1I2CYP19A1ESR1ESR2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951217-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-08-12 EP claimed
EP-1951217-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP claimed
WO-2007062148-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO claimed
EP-1951217-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-08-12 EP disclosed
US-20080234199-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-25 US disclosed
US-20080234199-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-25 US disclosed
US-20080234199-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-25 US disclosed
EP-1951217-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
WO-2007062148-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234199-A1 Chemical Compounds GPER1, ESR2, ESR1 NR1I2 15/4885CYP19A1 7/4885ESR1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.